Results per Page:
New biomarker could one day help tailor immunotherapy for Merkel cell carcinoma
Helps explain why only certain MCC patients respond to immune checkpoint inhibitors, could point toward new strategies to improve treatment responses
How RNA-altering drugs might improve anticancer immunotherapies
In lab study, brief disruptions of gene machinery make tumor cells more 'visible' to immune system
Breaking down HIV exclusions in cancer clinical trials
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
For cancer patients with HIV, immunotherapy appears safe
Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials
The tumor microenvironment: How cancer fools healthy neighboring cells
‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients
A new blood test detects recurrence of rare skin cancer
$200 assay can accurately signal return of Merkel cell carcinoma — in some cases catching tumors earlier than expensive imaging
Scratching the surface of a rare skin cancer
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma